About Sunovion
Sunovion is a Healthcare company based in Marlborough (United States) founded in 1984, and was acquired by Sumitomo Dainippon Pharma in August 2021. Pharmaceutical company that specializes in treatment of CNS and respiratory ailments. Sunovion has completed 2 acquisitions, including Cynapsus Therapeutics and Elevation Pharmaceuticals. Its website sunovion.com draws about 11 thousand monthly visits. Sunovion offers products and services including Drug Pipeline and Cell and Gene Therapies. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Sumitomo Pharma America, Inc.
Company details
Sunovion engages in discovering, developing, and commercializing therapeutic products for patients suffering from central nervous system disorders, respiratory disorders and other illnesses. Products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Zetonna (ciclesonide) Nasal Aerosol, and Alvesco (ciclesonide) Inhalation Aerosol. Pipeline includes latuda for pediatric schizophrenia, SUN-101 for COPD, dasotraline for ADHD and binge eating disorder, SB-623 for chronic stroke, SEP-856 for schizophrenia, DSP-2230 for neuropathic pain, DSP-3748 for cognitive impairment associated with schizophrenia and WT-2725 for hematologic and solid cancer.
- Headquarters Marlborough, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website sunovion.com
- Social LinkedIn X
- Acquired by Sumitomo Dainippon Pharma (Aug 2021)
- Legal Name Sumitomo Pharma America, Inc.
- Investors
- Investments & AcquisitionsCynapsus Therapeutics
& 1 more
- Acquired bySumitomo Dainippon Pharma
(Aug 2021)
Products & Services of Sunovion
Sunovion offers a comprehensive portfolio of products and services, including Drug Pipeline and Cell and Gene Therapies.
Advances drugs for oncology and rare diseases through clinical trials
Develops treatments for genetic and rare conditions
Investors in Sunovion
Sunovion has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sumitomo Dainippon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured. | 1897 | ds-pharma.com | Osaka, Japan |
Investor details for Sunovion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sunovion
6 people are tracked at Sunovion (5 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Stephen Freeman | EVP & Chief Financial Officer | Leadership |
Antony Loebel | President & CEO | Leadership |
Linda Arsenault | SVP, Chief Human Resources Officer | Leadership |
Yumi Sato | EVP & Chief Corporate Strategy Officer | Leadership |
Armin Szegedi | SVP & Chief Medical Officer | Leadership |
Greg Bokar | EVP, General Counsel & Corporate Secretary | Team |
Complete people profiles for Sunovion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sunovion
Sunovion has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cynapsus Therapeutics and Elevation Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Treatments for CNS disorders, including Parkinson's OFF episodes, are developed. | cynapsus.ca | Toronto, Canada | 2004 | Aug 2016 | •••• | |
Developer of aerosol drug products for COPD patients | elevationpharma.com | San Diego, United States | 2007 | Aug 2012 | $430M |
Complete acquisition details for Sunovion
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sunovion
4 dated milestones of Sunovion across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Sunovion is founded.
- Acquisition Acquires Elevation Pharmaceuticals.
- Acquisition Acquires Cynapsus Therapeutics.
- Exit Acquired by Sumitomo Dainippon Pharma.
Web traffic of Sunovion
The website of Sunovion (sunovion.com) receives about 11.4K visits a month and ranks #4,229,536 among all websites worldwide, #5,220 in Biotechnology and Pharmaceuticals.
- Monthly visits11.4K
▲ 137.5% vs previous month
- Unique visitors2.6K
per month
- Global rank#4,229,536
among all websites
- Category rank#5,220
Health · Biotechnology and Pharmaceuticals
- Bounce rate93%
- Pages per visit1.3
- Average visit29 sec
- DevicesDesktop 4% · Mobile 96%
Websites whose visitors overlap most with Sunovion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ds-pharma.com | 100% | View details | |||
| pfizer.com | 91% | 1.9M | #24,984 | View details | |
| novartis.com | 83% | 948.8K | #58,822 | View details | |
| biocentury.com | 81% | 85.7K | #514,907 | View details | |
| takeda.com | 78% | 620.1K | #93,966 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Sunovion
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Sunovion (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sunovion
Complete news archive for Sunovion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sunovion
Sunovion was founded in 1984.
Sunovion is headquartered in Marlborough, United States. It is registered at Marlborough, Massachusetts, United States.
Sunovion engages in discovering, developing, and commercializing therapeutic products for patients suffering from central nervous system disorders, respiratory disorders and other illnesses. Products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Zetonna (ciclesonide) Nasal Aerosol, and Alvesco (ciclesonide) Inhalation Aerosol. Pipeline includes latuda for pediatric schizophrenia, SUN-101 for COPD, dasotraline for ADHD and binge eating disorder, SB-623 for chronic stroke, SEP-856 for schizophrenia, DSP-2230 for neuropathic pain, DSP-3748 for cognitive impairment associated with schizophrenia and WT-2725 for hematologic and solid cancer.
Sunovion offers Drug Pipeline and Cell and Gene Therapies.
Sunovion has made 2 acquisitions, including Cynapsus Therapeutics, and Elevation Pharmaceuticals.
Sunovion has 1 investor. Key investors include Sumitomo Dainippon Pharma.
Sunovion operates through Sumitomo Pharma America, Inc..
Yes. Sunovion was acquired by Sumitomo Dainippon Pharma in August 2021.